CA2872188C - Methods and compositions for treatment of traumatic brain injury and for modulation of migration of neurogenic cells - Google Patents

Methods and compositions for treatment of traumatic brain injury and for modulation of migration of neurogenic cells Download PDF

Info

Publication number
CA2872188C
CA2872188C CA2872188A CA2872188A CA2872188C CA 2872188 C CA2872188 C CA 2872188C CA 2872188 A CA2872188 A CA 2872188A CA 2872188 A CA2872188 A CA 2872188A CA 2872188 C CA2872188 C CA 2872188C
Authority
CA
Canada
Prior art keywords
cells
polynucleotide
subject
mscs
tbi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2872188A
Other languages
English (en)
French (fr)
Other versions
CA2872188A1 (en
Inventor
Cesar V. Borlongan
Casey C. Case
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanbio Inc
University of South Florida St Petersburg
Original Assignee
Sanbio Inc
University of South Florida St Petersburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanbio Inc, University of South Florida St Petersburg filed Critical Sanbio Inc
Publication of CA2872188A1 publication Critical patent/CA2872188A1/en
Application granted granted Critical
Publication of CA2872188C publication Critical patent/CA2872188C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2872188A 2012-05-16 2013-03-13 Methods and compositions for treatment of traumatic brain injury and for modulation of migration of neurogenic cells Active CA2872188C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261647893P 2012-05-16 2012-05-16
US61/647,893 2012-05-16
PCT/US2013/030895 WO2013172944A1 (en) 2012-05-16 2013-03-13 Methods and compositions for treatment of traumatic brain injury and for modulation of migration of neurogenic cells

Publications (2)

Publication Number Publication Date
CA2872188A1 CA2872188A1 (en) 2013-11-21
CA2872188C true CA2872188C (en) 2018-08-14

Family

ID=48040424

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2872188A Active CA2872188C (en) 2012-05-16 2013-03-13 Methods and compositions for treatment of traumatic brain injury and for modulation of migration of neurogenic cells

Country Status (7)

Country Link
US (4) US9828593B2 (https=)
EP (1) EP2849766B1 (https=)
JP (6) JP6134783B2 (https=)
CN (3) CN104519891B (https=)
AU (2) AU2013263417B2 (https=)
CA (1) CA2872188C (https=)
WO (1) WO2013172944A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104519891B (zh) * 2012-05-16 2019-03-22 桑比欧公司 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物
HK1208371A1 (en) 2012-10-09 2016-03-04 桑比欧公司 Methods and compositions for treatment of retinal degeneration
US20170065638A1 (en) * 2014-02-10 2017-03-09 Cytori Therapeutics, Inc. Regenerative cell therapy for central nervous system (cns) disorders and ptsd
CA2981523A1 (en) * 2015-04-01 2016-10-06 Sanbio, Inc. Methods and compositions for stimulation of cell proliferation and provision of biologically active mixtures of fgf2 isoforms
US10555972B2 (en) * 2016-02-26 2020-02-11 Innopeutics Corporation Therapeutic effects of NURR1 and FOXA2 in inflammatory neurologic disorders by M1-to-M2 polarization of glial cells
WO2017152035A1 (en) * 2016-03-03 2017-09-08 Henry Ford Health System 3-d collagen scaffold-generated exosomes and uses thereof
JP7220149B2 (ja) 2016-12-28 2023-02-09 サンバイオ，インコーポレイティド 細胞送達システム及びその動作方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US20030003090A1 (en) 2001-05-31 2003-01-02 Prockop Darwin J. Directed in vitro differentiation of marrow stromal cells into neural cell progenitors
JP3886346B2 (ja) 2001-06-22 2007-02-28 サンバイオ，インコーポレイティド 骨髄間質細胞由来Ｓｃｈｗａｎｎ細胞を含む神経再生用医薬組成物
CN101584869B (zh) * 2002-02-06 2013-03-27 桑比欧公司 通过导入notch基因将骨髓基质细胞诱导分化为神经细胞或骨骼肌细胞的方法
EP1644026A4 (en) * 2003-06-12 2007-10-24 Ms Science Corp SIGMA LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RECREATION
CA2929754A1 (en) 2004-04-12 2005-10-27 Sanbio Inc. Cells exhibiting neuronal progenitor cell characteristics
AU2006220696B2 (en) 2005-03-07 2010-08-19 Sanbio, Inc. Use of neuronal precursor cells for treatment of central nervous system lesions
CN101008033A (zh) * 2006-01-27 2007-08-01 陈云 功能性中枢神经损伤诊断检测用基因芯片及其制造方法
WO2008102460A1 (en) 2007-02-23 2008-08-28 Sanbio Inc. Transplantation of bone marrow stromal cell-induced neural stem cells for promoting fuctional recovery after spinal cord injury
JP5662147B2 (ja) * 2007-08-15 2015-01-28 サンバイオ，インコーポレイティド 神経変性を治療するための方法及び組成物
WO2009073178A1 (en) 2007-12-03 2009-06-11 Sanbio, Inc. Extracellular matrix from pluripotent cells
ES2787513T3 (es) 2007-12-03 2020-10-16 Sanbio Inc Métodos y composiciones para modular la diferenciación de células pluripotenciales
JP5746016B2 (ja) 2008-04-30 2015-07-08 サンバイオ，インコーポレイティド Ｄｎａメチル化における改変を伴う神経再生細胞連邦政府の援助に関する申告適用なし
CA2832356C (en) 2011-04-06 2017-12-19 Sanbio, Inc. Methods and compositions for modulating peripheral immune function
US20120263681A1 (en) 2011-04-12 2012-10-18 Fujifilm Corporation Composition comprising cell and biocompatible polymer
EP2744891B1 (en) 2011-08-19 2018-12-12 SanBio, Inc. Neurogenic and gliogenic factors and assays therefor
EP2806881A1 (en) 2012-01-27 2014-12-03 SanBio, Inc. Methods and compositions for modulating angiogenesis and vasculogenesis
CN104519891B (zh) * 2012-05-16 2019-03-22 桑比欧公司 用于治疗创伤性脑损伤和用于调节神经原性细胞迁移的方法和组合物

Also Published As

Publication number Publication date
CN104519891B (zh) 2019-03-22
US20200354709A1 (en) 2020-11-12
US20150197741A1 (en) 2015-07-16
JP2015517520A (ja) 2015-06-22
JP2023099213A (ja) 2023-07-11
EP2849766A1 (en) 2015-03-25
US9828593B2 (en) 2017-11-28
US20190185839A1 (en) 2019-06-20
JP2018111733A (ja) 2018-07-19
WO2013172944A1 (en) 2013-11-21
HK1206631A1 (en) 2016-01-15
JP2016220694A (ja) 2016-12-28
JP2021098738A (ja) 2021-07-01
CA2872188A1 (en) 2013-11-21
AU2016204910B2 (en) 2017-07-20
AU2016204910A1 (en) 2016-08-04
JP6134783B2 (ja) 2017-05-24
CN115381855A (zh) 2022-11-25
CN104519891A (zh) 2015-04-15
AU2013263417A1 (en) 2014-11-20
US10626389B2 (en) 2020-04-21
JP2025098021A (ja) 2025-07-01
EP2849766B1 (en) 2019-03-06
US20140186316A1 (en) 2014-07-03
CN109718250B (zh) 2022-08-30
AU2013263417B2 (en) 2016-05-26
CN109718250A (zh) 2019-05-07

Similar Documents

Publication Publication Date Title
US10626389B2 (en) Methods and compositions for modulation of migration of neurogenic cells
ES2716015T3 (es) Procedimiento para tratar los efectos de un accidente cerebrovascular
JP6869303B2 (ja) 細胞増殖の刺激のための方法及び組成物、ならびにｆｇｆ２アイソフォームの生物学的に活性な混合物の提供
JP6193214B2 (ja) 歯髄由来の多能性幹細胞の製造方法
HK40077940A (en) Methods and compositions for treatment of traumatic brain injury and for modulation of migration of neurogenic cells
HK1206631B (en) Cells for use in the treatment of brain injury
HK40007760A (en) Methods and compositions for treatment of traumatic brain injury and for modulation of migration of neurogenic cells
HK40007760B (en) Methods and compositions for treatment of traumatic brain injury and for modulation of migration of neurogenic cells
HK40010333B (en) Method of treating the effects of stroke
HK1196540B (en) Method of treating the effects of stroke
HK1196540A (en) Method of treating the effects of stroke

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141114

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250224

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251006

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260226

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260226